Recalls & Responsibility

Wechsler, Jill
August 2010
Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p24
The article reports on the challenges of pharmaceutical executives in addressing manufacturing failures and regulatory violations after the recall of the nonprescription drugs of Johnson & Johnson's McNeil unit in the U.S. Joshua Sharfstein, principal deputy commissioner of Food and Drug Administration (FDA), states that the recall reflects the company's pattern of noncompliance with quality control requirements. Senator Charles Grassley notes that FDA plans to increase misdemeanor prosecutions.


Related Articles

  • FDA tried to sit on heart risk, Sen. says.  // Drug Store News;10/25/2004, Vol. 26 Issue 14, p11 

    Reports on Senator Charles Grassley's criticism against the U.S. Food and Drug Administration (FDA) for pandering to the interests of the pharmaceutical industry in the wake of the Vioxx recall. Grassley's claim that the FDA attempted to censor one of its own researchers, David Graham, from...

  • McNeil Controversy Spurs Call for Mandatory FDA Recall Power. Young, Donna // BioWorld Today;6/1/2010, Vol. 21 Issue 104, p3 

    The article analyzes the plan of the U.S. House Oversight and Government Reform Committee to make a law which will give the U.S. Food and Drug Authority (FDA) mandatory recall authority following the removal of more than 136 million bottles of children's medicines of McNeil Consumer Healthcare...

  • FDA Waves a Big Stick. Wechsler, Jill // Pharmaceutical Technology;Jun2009, Vol. 33 Issue 6, p30 

    The article reports on the stricter enforcement of food and drug safety and quality measures by the U.S. Food and Drug Administration (FDA). It relates that in response to a series of food contamination and raised charges of lax on its rules, FDA's acting commissioner, Joshua Sharfstein...

  • Johnson and Johnson's Recall of Children's Tylenol and Other Children's Medicines and The Phantom Recall of Motrin (Part 2). Sharfstein, Joshua M. // Biomedical Market Newsletter;12/20/2010, p79 

    The article reports that the Johnson and Johnson has recalled several children's medicine including Tylenol and Motrin. First, Food and Drug Administration (FDA) is investigating whether any serious illnesses or deaths have been linked to the recalls. Extensively investigated adverse events...

  • Checks and Balances. Studt, Tim // Laboratory Equipment;Jun2010, Vol. 47 Issue 2, p6 

    The article offers the author's insights on the failure of Johnson & Johnson (J&J) to properly administer quality control on its products. It says that the company has recalled their over the counter (OTC) drugs in January 2010 due to odor complaints and their liquid OTC for children in May...

  • Grassley, Kohl argue for more FDA control of device recalls. McCARTY, MARK // Medical Device Daily;6/23/2011, Vol. 15 Issue 116, p1 

    The article reports on the statement of Senators Chuck Grassley and Herb Kohl that the U.S. Food and Drug Administration needs to be more involved in medical device recalls to better mitigate the risk of serious health consequences from defective or unsafe devices. Grassley believes that...

  • Antipsychotic add-on falls off FDA measure. O'Connor, John // McKnight's Long-Term Care News;Jul2012, Vol. 33 Issue 7, p1 

    The article offers information on the U.S. Senators, Herb Kohl, Charles Grassley, and Richard Blumenthal who passed proposed an amendment to the U.S. Food and Drug Administration for obtaining informed consent before administering off-label use of antipsychotics.

  • Overseeing Device Recalls. Mitka, Mike // JAMA: Journal of the American Medical Association;8/10/2011, Vol. 306 Issue 6, p598 

    The article reports that U.S. Senator Chuck Grassley has called on the U.S. Food and Drug Administration (FDA) to improve its assessment of medical devices recalls to reduce serious health risks from unsafe or defective devices.

  • FDA speaks out over decision to keep Avandia on market.  // Reactions Weekly;10/9/2010, Issue 1322, p6 

    The article reports on the explanation of Joshua Sharfstein, principal deputy director of the U.S. Food and Administration (FDA), about the decision of the agency to keep the drug Avandia (rosiglitazone) of GlaxoSmithKline (GSK) in the market despite issues on its cardiovascular risks.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics